Update on medical treatment of uterine fibroids



      In this review paper, the pros and cons of the available pharmacological options for the treatment of uterine fibroids are explored, including oral progestogens, levonorgestrel intra-uterine device, gonadotropin-releasing hormone analogs and progesterone receptor modulators with an emphasis on ulipristal acetate.

      Study design

      The choice of the appropriate therapeutic approach for uterine fibroids depends on several factors, including women's age, parity, childbearing aspirations and wish to preserve fertility, extent and severity of symptoms, size, number and location of myomas, risk of malignancy and proximity to menopause. Some treatment algorithms have been proposed for uterine fibroids, considering both efficacy and safety data from clinical trials, and women characteristics and choices. Therefore, we propose two optimized treatment algorithms for the treatment of uterine fibroids, one for the treatment of uterine fibroids in women of reproductive age with the desire to spare reproductive capacity, and another for the treatment of uterine fibroids in women >40 years with no desire for pregnancy.


      Symptoms associated with uterine fibroids may significantly impair a patient quality of life. Therapy includes surgery, which may range from a hysterectomy to several other uterus-sparing techniques and several different types of pharmacological therapies. Studies with ulipristal acetate have provided a change of paradigm in the treatment of uterine fibroids, demonstrating the efficacy and favorable tolerability profile, not only for the preoperative treatment of moderate to severe fibroid-associated symptoms, but also, and very importantly, for the long-term medical management of patients with symptomatic fibroids.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Munro M.G.
        • Critchley H.O.
        • Broder M.S.
        • Fraser I.S.
        Figo working group on menstrual disorders: FIGO classification system for causes of abnormal uterine bleeding in nongravid women of reproductive age.
        Int J Gynaecol Obstet. 2011; 113: 1-13
        • Fields K.R.
        • Neinstein L.S.
        Uterine myomas in adolescents: case reports and a review of the literature.
        J Pediatr Adolesc Gynecol. 1996; 9: 195-198
        • Cramer S.F.
        • Patel A.
        The frequency of uterine leiomyomas.
        Am J Clin Pathol. 1990; 94: 435-438
        • Wallach E.
        • Nikos F.
        Vlahos uterine myomas: an overview of development, clinical features, and management.
        Obstetrics Gynecol. 2004; 104: 393-406
      1. AAGL practice report: practice guidelines for the diagnosis and management of submucous leiomyomas.
        J Minim Invasive Gynecol. 2012; 19: 152-171
        • Águas F.
        • Marques C.
        • da Silva D.P.
        • Faustino F.
        • Fradique A.
        • Vicente L.F.
        • et al.
        Consenso sobre Miomas Uterinos da Sociedade Portuguesa de Ginecologia.
        2013 (Retrieved from.
        • Downes E.
        • Sikirica V.
        • Gilabert-Estelles J.
        The burden of uterine fibroids in five European countries.
        Eur J Obstet Gynecol Reprod Biol. 2010; 152: 96-102
        • Singh S.S.
        • Belland L.
        Contemporary management of uterine fibroids: focus on emerging medical treatments.
        Curr Med Res Opin. 2015 Jan; 31: 1-12
        • Flynn M.
        • Jamison M.
        • Datta S.
        • Myers E.
        Health care resource use for uterine fibroid tumors in the United States.
        Am J Obstet Gynecol. 2006; 195: 955-964
        • van der Kooij S.M.
        • Ankum W.M.
        • Hehenkamp W.J.
        Review of nonsurgical/minimally invasive treatments for uterine fibroids.
        Curr Opin Obstet Gynecol. 2012; 24: 368-375
        • Society of Obstetricians and Gynaecologists of Canada
        SOGC clinical practice guidelines. Uterine fibroid embolization (UFE).
        Int J Gynaecol Obstet. 2005; 89: 305-318
        • Marret H.
        • Fritel X.
        • Ouldamer L.
        • Bendifallah S.
        • Brun J.L.
        • de Jesus I.
        • et al.
        Therapeutic management of uterine fibroid tumors: updated French guidelines.
        Eur J Obstet Gynecol Reprod Biol. 2012; 165: 156-164
        • Pron G.
        • Mocarski E.
        • Bennett J.
        Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial.
        Obstet Gynecol. 2005; 105: 67-76
        • Dutton S.
        • Hirst A.
        • McPherson K.
        A UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on medium-term safety and efficacy.
        BJOG: Int J Obstetrics Gynaecol. 2007; 114: 1340-1351
        • Lefebvre G.
        • Vilos G.
        • Allaire C.
        • et al.
        The management of uterine leiomyomas.
        J Obstet Gynaecol Can. 2003; 25: 19-22
        • Vilos G.A.
        • Daly L.J.
        • Tse B.M.
        Pregnancy outcome after laparoscopic electromyolysis.
        J Am Assoc Gynecologic Laparoscopists. 1998; 5: 289-292
        • American College of Obstetricians and Gynecologists
        ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas.
        Obstet Gynecol. 2008; 112: 387-400
        • Sayed G.H.
        • Zakherah M.S.
        • El-Nashar S.A.
        • Shaaban M.M.
        A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia.
        Int J Gynaecol Obstet. 2011; 112: 126-130
        • Venkatachalam S.
        • Bagratee J.S.
        • Moodley J.
        Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study.
        J Obstet Gynaecol. 2004; 24: 798-800
        • Murat Naki M.
        • Tekcan C.
        • Ozcan N.
        • Cebi M.
        Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes.
        Fertil Steril. 2010; 94: 371-374
        • Engel J.B.
        • Audebert A.
        • Frydman R.
        • Zivny J.
        • Diedrich K.
        Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study.
        Eur J Obstet Gynecol Reprod Biol. 2007; 134: 225-232
        • Felberbaum R.E.
        • Germer U.
        • Ludwig M.
        Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist cetrorelix.
        Hum Reprod. 1998; 13: 1660-1668
        • Flierman P.A.
        • Oberyé J.J.
        • van der Hulst V.P.
        • de Blok S.
        Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.
        BJOG. 2005; 112: 638-642
        • De Leo V.
        • la Marca A.
        • Morgante G.
        Short-term treatment of uterine fibromyomas with danazol.
        Gynecol Obstet Invest. 1999; 47: 258-262
        • Telimaa S.
        • Puolakka J.
        • Rönnberg L.
        • Kauppila A.
        Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis.
        Gynecol Endocrinol. 1987; 1: 13-23
        • Lethaby A.
        • Vollenhoven B.
        • Sowter M.
        Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
        Cochrane Database Syst Rev. 2001; : CD000547
        • Donnez J.
        • Schrurs B.
        • Gillerot S.
        • Sandow J.
        • Clerckx F.
        Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
        Fertil Steril. 1989; 51: 947-950
        • Campo S.
        • Garcea N.
        Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues.
        Hum Reprod. 1999; 14: 44-48
        • Tan Y.H.
        • Lethaby A.
        Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding.
        Cochrane Database Syst Rev. 2013; : CD010241
        • Moroni R.M.
        • Martins W.P.
        • Ferriani R.A.
        • Vieira C.S.
        • Nastri C.O.
        • Candido dos Reis F.J.
        • Brito L.G.
        Add-back therapy with GnRH analogues for uterine fibroids.
        Cochrane Database Syst Rev. 2015; 3: CD010854
        • Shozu M.
        • Murakami K.
        • Segawa T.
        Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor.
        Fertil Steril. 2003; 79: 628-631
        • Deng L.
        • Wu T.
        • Chen X.Y.
        Selective estrogen receptor modulators(SERMs) for uterine leiomyomas.
        Cochrane Database Syst Rev. 2012; 10: CD005287
        • Halder S.K.
        • Goodwin S.
        • Al-Hendy A.
        • Vitamin D.
        exhibits antiestrogenic effects in human uterine leiomyoma cells.
        Fertil Steril. 2010; 94: S219-S220
        • Zhang D.
        • Al-Hendy M.
        • Richard-Davis G.
        • Montgomery-Rice V.
        • Rajaratnam V.
        • Al-Hendy A.
        Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells.
        Fertil Steril. 2010; 94: 1887-1893
        • Talaulikar V.S.
        • Manyonda I.
        Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids.
        Eur J Obstet Gynecol Reprod Biol. 2012; 165: 135-140
        • Bouchard P.
        • Chabbert-Buffet N.
        • Fauser B.
        Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety.
        Fertil Steril. 2011; 96: 1175-1189
        • Chabbert-Buffet N.
        • Pintiaux A.
        • Bouchard P.
        The imminent dawn of SPRMs in obstetrics and gynecology.
        Mol Cell Endocrinol. 2012; 358: 232-243
        • Rein M.S.
        • Barbieri R.L.
        • Friedman A.J.
        Progesterone: a critical role in the pathogenesis of uterine myomas.
        Am J Obstet Gynecol. 1995; 172: 14-18
        • Andersen J.
        Growth factors and cytokines in uterine leiomyomas.
        Semin Reprod Endocrinol. 1996; 14: 269-282
        • Chegini N.
        Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder.
        Semin Reprod Med. 2010; 28: 180-203
        • Englund K.
        • Blanck A.
        • Gustavsson I.
        • Lundkvist Y.
        • Sjoblom P.
        • Norgen A.
        • et al.
        Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment.
        J Clin Endocrinol Metabol. 1998; 83: 4092-4096
        • Brandon D.D.
        • Erickson T.E.
        • Keenan E.J.
        Estrogen receptor gene expression in human uterine leiomyomata.
        J Clin Endocrinol Metabol. 1995; 80: 1876-1881
        • Brandon D.D.
        • Bethea C.L.
        • Strawn E.Y.
        Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas.
        Am J Obstet Gynecol. 1993; 169: 78-85
        • Ishikawa H.
        • Ishi K.
        • Serna V.A.
        Progesterone is essential for maintenance and growth of uterine leiomyoma.
        Endocrinology. 2010; 151: 2433-2442
        • Barbarisi A.
        • Petillo O.
        • Di Lieto A.
        • Melone M.A.
        • Margarucci S.
        • Cannas M.
        • et al.
        17-Estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway.
        J Cell Physiol. 2001; 186: 414-424
        • Matsuo H.
        • Maruo T.
        • Samoto T.
        Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone.
        J Clin Endocrinol Metab. 1997; 82: 293-299
        • Chen W.
        • Ohara N.
        • Wang J.
        • Xu Q.
        • Liu J.
        • Morikawa A.
        • et al.
        A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
        J Clin Endocrinol Metab. 2006; 91: 1296-1304
        • Maruo T.
        • Ohara N.
        • Wang J.
        • Matsuo H.
        Sex steroidal regulation of uterine leiomyoma growth and apoptosis.
        Hum Reprod Update. 2004; 10: 207-220
        • Yamada T.
        • Nakago S.
        • Kurachi O.
        • Wang J.
        • Takekida S.
        • Matsuo H.
        • et al.
        Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells.
        Hum Reprod. 2004; 19: 815-821
        • Chwalisz K.
        • Perez M.C.
        • Demanno D.
        Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.
        Endocr Rev. 2005; 26: 423-438
        • Chabbert-Buffet N.
        • Meduri G.
        • Bouchard P.
        • Spitz I.M.
        Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications.
        Hum Reprod Update. 2005; 11: 293-307
        • Talaulikar V.S.
        • Manyonda I.T.
        Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids.
        Adv Ther. 2012; 29: 655-663
        • Talaulikar V.S.
        • Manyonda I.
        Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids.
        Eur J Obstet Gynecol Reprod Biol. 2012; 165: 135-140
        • Donnez J.
        • Tatarchuk T.F.
        • Bouchard P.
        • Puscasiu L.
        • Zakharenko N.F.
        • Ivanova T.
        • et al.
        Ulipristal acetate versus placebo for fibroid treatment before surgery.
        N Engl J Med. 2012; 366: 409-420
        • Donnez J.
        • Tomaszewski J.
        • Vázquez F.
        • Bouchard P.
        • Lemieszczuk B.
        • Baró F.
        • et al.
        Ulipristal acetate versus leuprolide acetate for uterine fibroids.
        N Engl J Med. 2012; 366: 421-432
        • Donnez J.
        • Vazquez F.
        • Tomaszewski J.
        • Nouri K.
        • Bouchart P.
        • Bart C.
        • et al.
        Long-term treatment of uterine fibroids with ulipristal acetate.
        Fertil Steril. 2014; 101: 1565-1573
        • Donnez J.
        • Hudecek R.
        • Donnez O.
        • et al.
        Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
        Fertil Steril. 2015; 103: 519-527
        • Donnez J.
        • Donnez O.
        • Matule D.
        • Arhendt H.J.
        • Hudecek R.
        • Zatik J.
        • et al.
        Long-term medical management of uterine fibroids with ulipristal acetate.
        Fertil Steril. 2016; 106: 165-173
        • Luyckx M.
        • Squifflet J.L.
        • Jadoul P.
        • Votino R.
        • Dolmans M.M.
        • Donnez J.
        First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids.
        Fertil Steril. 2014; 102: 1404-1409